FGFR2 and cholangiocarcinoma: These drugs exert a high therapeutic effect on the fusion gene among various structural mutations of FGFR. Of these, pemigatinib, an oral inhibitor of FGFR1, FGFR2, and FGFR3, was the earliest FDA-approved drug intended to be used in chemotherapy-resistant cholangiocarcinoma patients with the FGFR2 fusion gene or rearrangement [112].